source
- Skyhawk Therapeutics reports symptom improvement for Huntington's disease in Phase 1/2 extension studySkyhawk Therapeutics announced that its RNA-splicing candidate SKY-0515 showed a measurable improvement in symptoms for patients with Huntington's disease during an extension of its Phase 1/2 trial…
- Biotech firms race to hire AI-savvy scientists as talent gap widensAI is becoming integral to biotech research and development, prompting companies to seek staff who can blend biology with machine learning and data engineering. Recruiters say the hardest-to-find…